高级实践提供者对慢性乙型肝炎患者特征及诊疗质量的影响
这项回顾性分析利用2003至2021年Optum去标识化数据库纳入42140例慢性乙型肝炎患者,比较高级实践提供者(APP)辅助与仅医生诊疗的管理情况。34.3%患者接受APP诊疗且比例随时间上升;符合AASLD和EASL治疗标准者分别有62.8%和56.2%接受治疗,APP诊疗者接受治疗的可能性更高(AASLD调整HR 1.18,95%CI 1.03-1.34;EASL调整HR 1.24,95%CI 1.09-1.41)。
要点
- APP诊疗利用率随时间上升,34.3%患者接受APP诊疗。
- 基于AASLD和EASL标准,分别62.8%和56.2%符合治疗条件者接受了治疗。
- APP诊疗者接受抗病毒治疗的可能性更高(AASLD调整HR 1.18;EASL调整HR 1.24)。
核心结论
- 接受APP诊疗的符合治疗条件的慢性乙型肝炎患者更可能接受抗病毒治疗;APP诊疗可能有助于扩大慢性乙型肝炎的提供者队伍并改善当前不理想的治疗率。
研究设计与样本
- 回顾性分析,利用Optum去标识化Clinformatics® Data Mart数据库(2003-2021年)以ICD-9/ICD-10编码识别慢性乙型肝炎感染患者,纳入42140例符合条件患者(平均年龄51.9±15.1岁;56.1%男性)。
主要发现
- 总体34.3%患者接受APP诊疗,且APP利用率随时间上升。
- 与仅医生诊疗相比,同时接受APP诊疗的患者更可能有病毒合并感染,且更可能由专科医生看诊(72.1%)。
- 基于AASLD和EASL指南,分别有62.8%和56.2%符合治疗条件的患者接受了治疗。
- 调整年龄、性别、 race/ethnicity、病毒双重感染、基线肝硬化/肝癌、HBV DNA和丙氨酸氨基转移酶测量次数及医生提供者类型后,APP诊疗患者更可能接受治疗(AASLD调整HR 1.18,95%CI 1.03-1.34;EASL调整HR 1.24,95%CI 1.09-1.41)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced practice providers (APP) may be able to play a role in improving the linkage to care in patients with chronic hepatitis B (CHB), but data are limited. AIM: To compare management of patients with CHB under APP-assisted versus physician-only care METHODS: This retrospective analysis identified patients with CHB infection from Optum's de-identified Clinformatics® Data Mart Database (2003-2021) using ICD-9/ICD-10 codes. We compared the proportion of patients with CHB who had adequate evaluation for treatment (defined as ALT, HBV DNA, ± HBeAg), and the proportion of treatment-eligible patients with CHB who received treatment between APP versus physician-only care. RESULTS: We included 42,140 eligible patients (mean age: 51.9 ± 15.1; 56.1% male). Overall, 34.3% received APP care with increasing utilisation over time. Compared to physician-only care, patients who also received APP care were more likely to have viral co-infection, and more likely to have been seen by a specialist (72.1%). Overall, 62.8% and 56.2% of treatment-eligible patients based on AASLD and EASL guidelines, respectively, received treatment. APP care patients were more likely to be treated (AASLD adjusted HR: 1.18, 95%CI: 1.03-1.34; EASL adjusted HR:1.24, 95%CI: 1.09-1.41) after adjustment for age, sex, race/ethnicity, viral dual infection, baseline cirrhosis/liver cancer, number of HBV DNA and alanine aminotransferase measurements, and physician provider type. CONCLUSION: Treatment-eligible patients with CHB receiving APP care were more likely to receive antiviral therapy. APP care may help to expand the pool of providers for patients with CHB, and to improve current suboptimal treatment rates.
引用
- Kam LY, Huang DQ, Tobias AF, et al. Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022. PMID: 36266768. doi:10.1111/apt.17254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。